Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

18

Revenue 2017

Takeda

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Takeda's 2013 sales performance.

Takeda

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar is also holding on to the rights to test its drug alongside other drugs - it already has an alliance in place with Takeda for example - but for the time being

Another Alzheimer's bust as Merck stops verubecestat study

Another Alzheimer's bust as Merck stops verubecestat study Since the start of the year, Boehringer Ingelheim has stopped development of its PDE9a inhibitor BI 4093906, Takeda and Zinfandel abandoned efforts to repurpose diabetes drug pioglitazone for the disease, and

The good, the bad and the ugly

The good, the bad and the ugly AstraZeneca, Takeda, Astellas Pharma, Novo Nordisk and Recordati take up the final five positions, though only two - Takeda (3.9%) and Astellas (9.3%) - recorded growth. ... 2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer Meanwhile another new entrant - Alunbrig (brigatinib) from Takeda - is also making headway after its first approval in 2017, making $13m by the end of the calendar year.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics